secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hims & Hers Health, Inc. (HIMS)
CIK:        0001773751
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001773751-26-000010
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hims & Hers acquires Eucalyptus for up to $1.15B, expanding globally
--------------------------------------------------------------------

- Transaction valued up to $1.15B: ~$240M cash upfront, ~$710M deferred over 18 months, up to ~$200M earnouts.
- Eucalyptus has ARR >$450M, triple-digit YoY growth in 2025, and served >775,000 customers.
- Tim Doyle, Eucalyptus CEO, to become SVP of International at Hims & Hers post-close.
- Acquisition expected to close mid-2026, subject to regulatory approvals and customary conditions.
- Hims & Hers to finance with existing cash and US operating cash flows; option to settle payments in stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1773751/000177375126000010/0001773751-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1773751/000177375126000010/hims-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001773751-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer